The European Medical Society of Oncology (ESMO) Congress is a must for any oncology professional, with experts from across the globe gathering at the event to discuss all-new trial readouts and promising emerging treatment options.

The conference, which covers everything from solid tumours to haematological malignancies, brings in a wide variety of participants – from biotech and pharma companies to healthcare professionals and investors.

At this year’s event, there was no shortage of interesting coverage, with key trial readouts across breast and endometrial cancer, as well as head and neck squamous cell carcinoma (HNSCC) and colorectal malignancies.

In this podcast, the healthcare editorial team catches up with Jack Cuthbertson, senior healthcare analyst at GlobalData, to discuss the highlights from this year’s ESMO 2025 Congress.

Alongside Clinical Trials Arena editor Abigail Beaney and reporter Annabel Kartal-Allen, Jack discusses the most prominent trends observed at the congress, as well as the market impact the notable readouts may have moving forward.

You can download GlobalData's ESMO 2025 highlights report here

You can also watch the immuno-oncology webinar on-demand here and read further expert commentary from GlobalData’s team here.